Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesMaurizio Callari, Giampaolo Bianchini, Marco Barreca et al.|Nature Communications|2025Cited by 5